Indivan capsule is an HIV (human immunodeficiency virus) protease inhibitor. The capsules are formulated as a sulfate salt and available for oral administration. Indivan is an antiviral drug which prevents HIV from proliferation in our body.
It is used to HIV as well as AIDS. Indivan is not a curable medicine for HIV and AIDS. It is a prescription drug recommended under guidance of medical practioners.
Indivan with concomitant use of other antiretroviral is indicated for the treatment of HIV infection. The uses is depends on two clinical trials almost 1 year duration that describes Reduction in the risk of AIDS-defining illnesses or death, A prolonged suppression of HIV RNA
MECHANISM OF ACTION
An enzyme HIV-1 protease is needed for the proteolytic gap of the viral polyprotein precursors fused to the individual functional proteins found in HIV-1 infectious. Indinavir joints to the protease active site and prohibits the activity of the enzyme. This prohibition prevents cleavage of the viral polyproteins causing in the formation of immature non-infectious viral particles.
Rapidly absorbed, time to high plasma protein is 0.8±0.3 hrs
human plasma protein bounds of Indivan is 60%
In hepatic is metabolized
< 20% of indinavir is eliminatedin the urine unchanged.
Half life of Indivan is 1.8 (±0.4) hours.
DOSAGE AND ADMINISTRATION
The usual dosage of Indivan is 800mg administer as two 400mg capsules given orally every 8 hours in combination with other antiretrovirals for the treatment of HIV infections. With Ritonavir then 800mg plus Ritonavir 100mg to 200mg twice a day The patients taking Indivan must be intervals of 8 hours
Indivan should administrated without food with water 1 hour before or 2 hours after meal It can be also taken with other liquids such as skim milk,juice,coffee or tea or with a light meal The patients ensure adequate hydration its prescribed adults drinks at least 1.5 liters of liquids during the course of 24 hours
Side effects by Clinical trials experience- adult and adolescents (13 yrs and older) Digestive system: diarrhea, nausea, flatulence, epigastric pain Skin /appendages: rash Hemic/lymphatic system: anemia, leucopenia and thrombocytopenia Metabolic/nutritional: liver function test abnormalities amylase, SGOT, SGPT, hypoglycemia, dehydration Musculoskeletal system: arthralgia, arthritis, cramps,myalgia Respiratory: dyspnae, pharyngitis, rhinitis, and sinusitis. Special sense: acute iritis and eye disorder.
Hypersensitivity reaction Qtc prolongation Jaundice Bilirubinemia, metabolic acidosis.
Nephrolithiasis events cumulative frequency increase with increasing exposure of Indivan hence risk over time remains the same
Acute hemolytic anemia involves cases reports in death. Hence discontinuation of Indivan
The patient having hepatitis has been treated with Indivan will leads to hepatic failure and death
The mechanism and long term consequence of these events are currently unknown. A causal relationship has not been established.
Combination of indinavir with drugs metabolized by CYP3A4 wills increases plasma concentration of the other drugs. Interaction with drugs that induce CYP3A4 activity will increase clearance of indinavir, resulting in reduced plasma concentrations of indinavir
Indivan contraindicated in Hypersensitivity to any of its components Inhibition of CYP3A4
There have no adequate and well developed studies in pregnant women. It should be used when potential benefit clarify the possible risk of the fetus
It is not known whether excreted in human milk, breast feeding mothers to be advice to discontinue if they receive Indivan.
Stored in tightly closed container and temperature at 15-30°C Dispense in original container.
If patients missed a dose then have the drug while you remember before next dose timing. Or skip the missed dose and follow regular schedule Please consult with the doctor.